Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC

Autor: Farrah B. Khan, MD, Pamela C. Gibson, MD, Scott Anderson, MD, Sarah Wagner, BS, Bernard F. Cole, PhD, Peter Kaufman, MD, C. Matthew Kinsey, MD, MPH
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: JTO Clinical and Research Reports, Vol 5, Iss 3, Pp 100634- (2024)
Druh dokumentu: article
ISSN: 2666-3643
DOI: 10.1016/j.jtocrr.2024.100634
Popis: Neoadjuvant intratumoral cisplatin has the potential to generate substantial cytotoxicity and immune priming within the tumor environment, while minimizing systemic, off-target, adverse events. We initiated a phase 1A, 3+3 dose-ranging study of neoadjuvant, intratumoral cisplatin, delivered through endobronchial ultrasound bronchoscopy, in the same procedure as the initial diagnosis. There were no dose-limiting toxicity identified at the 20mg level
Databáze: Directory of Open Access Journals